跳至主要内容
临床试验/EUCTR2004-005018-35-DE
EUCTR2004-005018-35-DE进行中(未招募)不适用

Randomized, single-blind, multicentre study to compare the efficacy and safety of once daily 1 g mesalazine suppositories versus three times daily 0.5 g mesalazine suppositories in patients with acute ulcerative proctitis - OD vs. TID dosing with mesalazine suppositories in acute ulcerative proctitis

Dr. Falk Pharma GmbH0 个研究点目标入组 380 人开始时间: 2005年6月28日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
380

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - signed informed consent
  • - Man or woman between 18 and 75 years of age
  • - Active ulcerative proctitis, i.e. inflammation/lesions maximal 15 cm of rectum
  • - Diagnosis confirmed by endoscopy and histological examination
  • - Established disease or new diagnosis
  • - Mildly to moderately active ulcerative proctitis (3 < DAI < 11)
  • - Women of child-bearing potential have to apply appropriate contraceptive methods
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Crohn’s disease
  • - proctitis of a different origin
  • - Prior bowel resection leading to diarrhoea and/or pouch formation
  • - Toxic megacolon
  • - Hemorrhagic diathesis
  • - symptomatic organic disease of the gastrointestinal tract
  • - Active colorectal cancer or a history of colorectal cancer
  • - Active malignancy other than colorectal cancer or treatment with anticancer drugs during the last 5 years
  • - asthma, active peptic ulcer disease, infection
  • - Abnormal hepatic function or liver cirrhosis
  • - Abnormal renal function
  • - Regular oral treatment with more than 2 g/day 5-ASA, olsalazine or more than 5 g/day sulfasalazine within the last four weeks
  • - Regular rectal treatment with more than 0.5 g/day 5-ASA, olsalazine or more than 1 g/day sulfasalazine within the last four weeks
  • - Corticosteroid therapy within the previous one month
  • - Immunosuppressive drugs or anti-TNF-a therapy within the previous three months
  • - Application of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before baseline visit
  • - Known intolerance/hypersensitivity/resistance to study drugs or drugs of similar chemical structure or pharmacological profile
  • -Intake of Cycloferon within the last four weeks

研究者

相似试验

进行中(未招募)
1 期
Clinical study to investigate the efficacy and safety of a budesonide suppository for the treatment of acute ulcerative proctitisAcute ulcerative proctitis
EUCTR2012-003362-41-DEDr. Falk Pharma GmbH337
进行中(未招募)
不适用
Randomized, Double-blind, Multicenter study to compare the safety and efficacy of Viramidine to Ribavirin in Treatment-Naive patients with Chronic Hepatitis CChronic Hepatitis CMedDRA version: 6.1Level: PTClassification code 10019744
EUCTR2004-000408-41-ITRIBAPHARM
进行中(未招募)
不适用
clinical trial to evaluate the effectiveness of two administration schedules of CitraFleet to cleanse the colo
EUCTR2013-001620-20-DEaboratorios Casen-Fleet S.L.U.320
进行中(未招募)
不适用
Randomized, multicenter, double blind study to compare the efficacy and tolerability of Oleogel-S-10 for 3 months versus placebo only in patients with mild to moderate ac-tinic keratoses located at the face and head - BETA-TrialDie Studie ist eine randomisierte, multizentrische, doppelt verblindete Studie zum Vergleich der Wirksamkeit und Verträglichkeit einer Behandlung mit Oleogel-S-10 über 3 Monate vs. Placebo bei Patienten mit gering- bis mittelgradigen aktinischen Keratosen des Kopfes inkl. des Gesichtes. Ziel der Studie ist es, die Wirksamkeit und die Tolerabilität dieser Behandlung zu prüfen.
EUCTR2008-002632-15-DEBirken GmbH162
进行中(未招募)
1 期
An examination of which type of medicine (rocuronium or remifentanil) is better concerning placement of a tube in trachea in elderly patients under going anesthesiaThe aim of this study is to determine the effect on intubating conditionsand laryngeal morbidity after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in patients with age = 80 years.MedDRA version: 21.1Level: LLTClassification code 10002323Term: Anesthesia generalSystem Organ Class: 100000004865
EUCTR2019-004121-25-DKRigshospitalet74